Did You Know...
...that when IBM conducted a market study of Chester Carlson's invention in 1959, the company concluded that it would take only 5000 units of his new product to saturate the market? IBM therefore declined to be part of the new product introduction. Too bad for IBM. Carlson's invention was the xerography process, and his new product was the beginning of the Xerox Corporation. It is estimated that every day, worldwide, 3,000,000,000 copies are made!!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8138154 | Biglycan and related therapeutics and methods of use The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophi... | 03/20/2012 |
| 7371723 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 05/13/2008 |
| 7351435 | Deglycosylated ricin toxin a-chain vaccine The present invention relates to a vaccine comprising deglycosylated ricin toxin A-chain and method for making and using the composition. ... | 04/01/2008 |
| 7335637 | Biglycan and related therapeutics and methods of use The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophi... | 02/26/2008 |
| 7326681 | Methods for producing modified glycoproteins Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield g... | 02/05/2008 |
| 7285635 | Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio... | 10/23/2007 |
| 7202225 | Therapeutic delivery compositions and methods of use thereof The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic ac... | 04/10/2007 |
| 7160856 | α-O-linked glycoconjugates, methods of preparation and uses thereof The present invention provides novel α-O-linked glycoconjugates such as α-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tum... | 01/09/2007 |
| 7150872 | Polyalkylene oxide-modified single chain polypeptides The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimens... | 12/19/2006 |
| 7118737 | Polymer-modified synthetic proteins The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological activity or pharmacokinetic properties. The invention further provides met... | 10/10/2006 |
| 7119074 | Treatment of cancers, tumors and malignancies using amphiphilic prodrugs The present invention provides amphiphilic prodrugs comprising a therapeutic compound conjugated to an PEG-oligomer/polymer and methods for using said prodrugs to enable oral drug delivery and/or delivery of drugs across the blood brain barrier into the central nerv... | 10/10/2006 |
| 7112564 | Biodegradable glucosaminemuramyl peptides for apoptosis modulation The endopeptidase hydrolysis of cross link peptide bond of the peptidoglycans results in release of the novel glucosaminemuramyl tri, tetra, penta, hexa, and octapeptides. Their structure is defined by specific endopeptidase cleavage as well as genus of gram positiv... | 09/26/2006 |
| 7083798 | Method of immunomodulatory treatment of insulin dependent diabetes mellitus using mycobacterial cell wall compositions The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, ... | 08/01/2006 |
| 7067639 | Method to provide bacterial ghosts provided with antigens Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating... | 06/27/2006 |
| 7037893 | Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis Glycopeptides capable of identifying multiple sclerosis antibodies, and therefore useful as diagnostic tools or for the treatment of said pathology are described. ... | 05/02/2006 |
| 7001907 | Peptide-containing α-ketoamide cysteine and serine protease inhibitors This invention relates to peptide-containing α-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same. ... | 02/21/2006 |
| 6960452 | Enzyme-mediated modification of fibrin for tissue engineering: incorporation of proteins Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as... | 11/01/2005 |
| 6932972 | Combined vaccine compositions Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen... | 08/23/2005 |
| 6921537 | Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are abl... | 07/26/2005 |
| 6903100 | USE OF REGULARLY SCHEDULED HIGH DOSE INTRAVENOUS METHOTREXATE THERAPY, WITH INTERIM ADMINISTRATION OF IMMUNOMODULATORY AGENTS, TO TREAT MULTIPLE SCLEROSIS AND OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM The present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of t... | 06/07/2005 |
| 6869607 | Vaccine formulations A vaccine containing one or more synthetic or highly purified natural peptides or proteins as antigen(s) as well as one or more adjuvants is present in the form of a solution or emulsion which is free from inorganic salt ions or has a low concentration of salt ions.... | 03/22/2005 |
| 6824793 | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same. ... | 11/30/2004 |
| 6790448 | Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface protein... | 09/14/2004 |
| 6764682 | Adjuvant compositions containing more than one adjuvant Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect a... | 07/20/2004 |
| 6743431 | Capsular polysaccharide adhesin antigen, preparation, purification and use A substantially pure capsular exopolysaccharide adhesin of coagulaso-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and mono-clonal an... | 06/01/2004 |
| 6723344 | Controlled release of non heparin-binding growth factors from heparin-containing matrices Matrices that support cell adhesion and growth are disclosed that deliver low heparin-binding affinity growth factor protein peptides in a controlled manner. These matrices comprise covalently or non-covalently bound heparin or heparin-like polymers, which serve to ... | 04/20/2004 |
| 6692752 | Methods of treating human females susceptible to HSV infection A method of administering a vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases is described. The vaccine comprises one or more antigens for the prevention or treatment of sexually transmit... | 02/17/2004 |
| 6673357 | Alkaloid glycoside for use as a medicament The invention concerns an alkaloid glycoside for use in medicine. In a preferred aspect, the alkaloid glycoside is used for the stimulation of a class I-restricted immune response and/or a class II-restricted immune response. In a preferred aspect, the al... | 01/06/2004 |
| 6649170 | Adjuvant combinations for immunization composition and vaccines A kit useful for immunization is described. The kit contains an antigenic substance from a Mycobacterium and an adjuvant combination of dimethyl dioctadecyl ammonium bromide and monophosphoryl lipid A.... | 11/18/2003 |
| 6607732 | ISCOM or ISCOM-matrix comprising a mucous targetting substance and an antigen An immunogenic complex includes at least one glycoside and at least one lipid. The complex further contains a) at least one mucosal surface targeting protein, protein derivative or carbohydrate that targets lymphatic tissue and induces an immune response ... | 08/19/2003 |
| 6582697 | Enhancement of the cellular immune response DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or the... | 06/24/2003 |
| 6572867 | Inhibition of xenoreactive antibodies One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter "xenopolymer") effective for in... | 06/03/2003 |
| 6572858 | Uses for anti-malarial therapeutic agents A diversity of inflammatory diseases can be treated via local delivery to the patient of a composition containing a therapeutically effective amount of an anti-malarial agent. In a preferred embodiment of the method of the invention, a pulmonary inflammat... | 06/03/2003 |
| 6444210 | Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity The present invention relates to the effects of bacterial polysaccharides on cell mediated immunity in animals. Polysaccharides of the present invention comprise the outer polysaccharides (OPS) located on bacterial cell membranes and other polysaccharides... | 09/03/2002 |
| 6440426 | Antigen-containing formulation and methods of use thereof An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvants; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvants may be, for example, monophosphoryl lipid A, 3'-de-O-acetylated monophos... | 08/27/2002 |
| 6432411 | Recombinant envelope vaccine against flavivirus infection A vaccine contains at least one Drosophila cell-secreted, recombinantly-produced form of a truncated Flavivirus envelope glycoprotein, as an active ingredient, and an adjuvant, as a critical component of the vaccine. The adjuvant is an immunomodulating ag... | 08/13/2002 |
| 6406705 | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid ad... | 06/18/2002 |
| 6399078 | Chemokine--glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases The present invention provides therapeutic compositions of receptor ligand-containing antagonist complexes and methods of using them to treat diseases, disorders or conditions associated with the function or aberrant function of a cell surface receptor.... | 06/04/2002 |
| 6355253 | Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are... | 03/12/2002 |
| 6355256 | Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof The invention involves the combination of Interleukin-12 with p53 derived peptides and an adjuvant, preferably QS-21. It is found that this combination provokes a surprisingly strong immune response. Further, in an accepted in vivo model, the use of compo... | 03/12/2002 |
